Our Science

Maureen Murphy, Ph.D.

Maureen Murphy, Ph.D.

  • Professor and Program Leader, Molecular and Cellular Oncogenesis Program
  • Associate Vice President for Faculty Affairs
  • Associate Director for Education and Career Development, Wistar Cancer Center
  • 215-495-6870, Office

The Murphy laboratory focuses on the most frequently mutated gene in human cancer, the tumor suppressor protein p53.  Murphy’s interest in apoptosis and p53 relates to how genetic polymorphisms in the p53 tumor suppressor gene that are more common in African Americans affect the ability of this protein to induce apoptosis and growth arrest, and hence combat tumor development. Her studies have relevance for understanding inter-individual differences in cancer risk and therapy, particularly in ethnic populations where these variants occur with high frequency.

In addition, the Murphy laboratory focuses on a cancer-critical survival protein called HSP70.  HSP70 is highly expressed in the majority of human tumors, but is largely undetectable in normal cells.  As such, HSP70 is an ideal cancer target.  Murphy uses a series of novel HSP70 inhibitors for the therapy of human tumor, with focus on melanoma.  She also seeks to understand why tumors that express high levels of HSP70 are more aggressive, and are associated with poorer prognosis.

Murphy obtained a bachelors of science degree in biochemistry at Rutgers University, followed by a doctorate in molecular biology at the University of Pennsylvania School of Medicine. In 1994, she began postdoctoral research at Princeton University in the laboratory of Arnold J. Levine, Ph.D., the co-discoverer of p53 and a pioneer in the field of tumor suppressor genes and cancer biology.

In 1998, Murphy became an Assistant Professor at Fox Chase Cancer Center, where she was promoted to Associate Professor in 2003, and Full Professor in 2011. She is also an adjunct professor at Drexel University College of Medicine and The Perelman School of Medicine at the University of Pennsylvania. Since 1999, she has received continuous research support from the National Cancer Institute for her studies. Murphy joined The Wistar Institute’s Molecular and Cellular Oncogenesis Program, and in 2012 she became Program Leader.

Selected Publications

1. Azzam GA, Wang X, Bell DA and Murphy ME.  CSF1 is a novel p53 target gene whose protein product functions in a feed-forward manner to suppress apoptosis and enhance p53-mediated growth arrest.  PLoS One, in press.

2. Budina-Kolomets A, Hontz RD, Pimkina J, Murphy ME. A conserved domain in exon 2 coding for the human and murine ARF tumor suppressor protein is required for autophagy induction. Autophagy 2013; Aug 7;9(10).  PMID: 23939042

3. Murphy ME. The HSP70 family and cancer. Carcinogenesis 2013; 34(6):1181-8. PMID: 23563090

4. Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G, Herlyn M, Villanueva J, Dunbrack RL Jr, Yen T, George DL, Murphy ME.  A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res 2013;11(3):219-29. PMID: 23303345

5. Leu JI, Pimkina J, Pandey P, Murphy ME, George DL.  HSP70 inhibition by the small-molecule 2-phenylethynesulfonamide impairs protein clearance pathways in tumor cells. Mol Cancer Res. 2011; 9:936-47. PMID: 21636681

6. Azzam GA, Frank AK, Hollstein M, Murphy ME. Tissue-specific apoptotic effects of the p53 codon 72 polymorphism in a mouse model. Cell Cycle 2011;10:1352-5. PubMed PMID: 2156645

7. Frank, AK, Leu JI, Zhou Y, Devarajan K, Nedelko T, Klein-Szanto A, Hollstein M, Murphy ME. The codon 72 polymorphism of p53 regulates interation with NF-{kappa}B and transactivation of genes involved in immunity and inflammation. Mol Cell Biol. 2011; 31:1201-13. PubMed PMID: 21245379; PubMed Central PMCID: PMC3067895.

8. Leu JI, Pimkina J, Frank A, Murphy ME, and George DL. A Small Molecule Inhibitor of Inducible Heat Shock Protein 70 (HSP70). Mol Cell 2009, 36:15-27. PMID: 19818706

9. Humbey O, Pimkina J, Zilfou JT, Jarnik M, Dominguez-Brauer C, Burgess DJ, Eischen CM, Murphy ME. The ARF tumor suppressor can promote the progression of some tumors. Cancer Res 2008; 68:9608-13. PubMed PMID: 19047137; PubMed Central PMCID:PMC2637809.

10. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33:357-65. PubMed PMID: 12567188.